SAN DIEGO, April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced presentations at the 75th American Academy of Neurology (AAN) Annual Meeting, including an oral presentation on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2 MARINA™ trial. The 75th AAN Annual Meeting is taking place in Boston, Mass., April 22-27, 2023.
ORAL PRESENTATION
April 27, 2023: 3:42 p.m. - 3:54 p.m. ET
POSTER PRESENTATION
April 23, 2023: 5:30 p.m. - 6:30 p.m. ET
Once available, both the presentation and poster will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Investor Contact:
Kathleen Gallagher
(858) 401-7900 x550
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Navjot Rai
(858) 401-7900 x550
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$26.45 |
| Daily Change: | 0.87 3.40 |
| Daily Volume: | 626,119 |
| Market Cap: | US$2.110B |
February 28, 2024 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
